

The FCA concludes PMPRB decision re Differin® exceeded the Board's jurisdiction

December 05, 2024

The Federal Court of Appeal (FCA) recently issued its decision in the appeal of Galderma's [second judicial review](#) of the decision of the Patented Medicines Price Review Board (the PMPRB) that it had jurisdiction over Galderma's Differin® product. In a strongly worded decision, the FCA granted Galderma's appeal and set aside the PMPRB's decision, holding that the PMPRB does not have jurisdiction over the price of the unpatented Differin® product.

History

This is the second time the FCA has adjudicated this dispute between Galderma and the PMPRB over whether Canadian Patent 2,478,237 (the '237 Patent) pertains to Galderma's Differin® product.

Galderma sells two products containing the medicinal ingredient adapalene: Differin® contains 0.1 per cent adapalene whereas Differin XP® contains 0.3 per cent. The patents pertaining to the Differin® product had expired. The '237 Patent relates to the Differin XP® product, and specifically the use of the 0.3 per cent concentration of adapalene. However, the PMPRB asserted that it also pertains to the Differin® product such that Galderma was required to provide pricing and other information about it to the PMPRB.

In 2016, the [PMPRB determined](#) that the '237 Patent does pertain to Differin®. However, in 2017, the [FC quashed that decision](#), holding that it was unreasonable for the Board, without explanation, to conclude that a patent relating to a composition of 0.3 per cent adapalene can be used for a medicine with a composition of only 0.1 per cent adapalene.

The Attorney General's appeal to the [Federal Court of Appeal \(FCA\)](#) was granted, and the decision was remitted to the Board for redetermination. The FCA held that the invention of the '237 Patent is a composition with a 0.3 per cent concentration of adapalene for the treatment of dermatological disorders.

In May 2020, the [PMPRB again determined](#) that the ‘237 Patent pertained to Differin®. This decision was [upheld by the Federal Court](#) in 2024. A more detailed history and a summary of the Federal Court decision [is found here](#).

The FCA decision

Justice Stratas, writing for the Court of Appeal, held that decades of jurisprudence confirms that the PMPRB can regulate the pricing of patented medicines, but not unpatented ones (para 5). The Court confirmed that the relevant provisions of the Patent Act are carefully drawn to give the PMPRB power within the Federal constitutional power over patents. The PMPRB “does not have any freestanding consumer protection or general price regulation mandate.” (Para 7) Those are provincial responsibilities.

The Court held that by ordering Galderma to produce pricing information pertaining to its Differin® product after it became unpatented, “the Board crashed through the constitutional, statutory, and jurisprudential guardrails.” (Para 10). The Court rejected the Board’s argument that the ‘237 Patent pertained to the Differin® product, writing “[T]he invention in the ‘237 Patent, the use of the 0.3% concentration of adapalene, cannot (in the words of subsection 79(2)) be “intended or capable of being used” for Differin or for “the preparation or production” of Differin, because Differin does not embody that use at all.” (Para 13)

The Court stated that in its earlier decision on this issue, it asked the PMPRB to re-examine the matter “on the basis that the invention of Canadian Patent No. 2,478,237 is the use of a 0.3 per cent concentration of adapalene for the treatment of dermatological disorders’ (at para. 6). But in no way did this Court give the Board a licence to go beyond constitutional, statutory, and jurisprudential limits. Nor could it.” (Para 14)

The Court did not decide the standard of review, as it held that “due to the absence of alternative options available to the administrative decision-maker on the facts of the case, correctness review and reasonableness review are indistinguishable and lead to the same result”. (Para 17) If the Board adopted and applied an indefensible and unacceptable interpretation of the Patent Act, it would be unreasonable. The FCA further confirmed that “the Board must temper its dedication and enthusiasm with a firm and unwavering obedience to legality and the rule of law.” (Para 19)

Thus, making the judgment the Federal Court should have made, the FCA granted the application for judicial review, and set aside the PMPRB’s order. Costs were agreed between the parties and fixed at \$20,000 in the FCA and below.

By

[Beverley Moore](#), [Chantal Saunders](#)

Expertise

[Intellectual Property](#), [Health Care & Life Sciences](#)

BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

blg.com

BLG Offices

Calgary

Centennial Place, East Tower
520 3rd Avenue S.W.
Calgary, AB, Canada
T2P 0R3

T 403.232.9500
F 403.266.1395

Ottawa

World Exchange Plaza
100 Queen Street
Ottawa, ON, Canada
K1P 1J9

T 613.237.5160
F 613.230.8842

Vancouver

1200 Waterfront Centre
200 Burrard Street
Vancouver, BC, Canada
V7X 1T2

T 604.687.5744
F 604.687.1415

Montréal

1000 De La Gauchetière Street West
Suite 900
Montréal, QC, Canada
H3B 5H4

T 514.954.2555
F 514.879.9015

Toronto

Bay Adelaide Centre, East Tower
22 Adelaide Street West
Toronto, ON, Canada
M5H 4E3

T 416.367.6000
F 416.367.6749

The information contained herein is of a general nature and is not intended to constitute legal advice, a complete statement of the law, or an opinion on any subject. No one should act upon it or refrain from acting without a thorough examination of the law after the facts of a specific situation are considered. You are urged to consult your legal adviser in cases of specific questions or concerns. BLG does not warrant or guarantee the accuracy, currency or completeness of this publication. No part of this publication may be reproduced without prior written permission of Borden Ladner Gervais LLP. If this publication was sent to you by BLG and you do not wish to receive further publications from BLG, you may ask to remove your contact information from our mailing lists by emailing unsubscribe@blg.com or manage your subscription preferences at blg.com/MyPreferences. If you feel you have received this message in error please contact communications@blg.com. BLG's privacy policy for publications may be found at blg.com/en/privacy.

© 2025 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.